Grants Search Results

Rhabdomyosarcoma (RMS) is a childhood cancer that affects muscle cells which attach to bones, affecting how a child moves, smiles, walks, and performs daily tasks. RMS can be very difficult to cure when it spreads. Children with metastatic or relapsed RMS have poor survival, and current treatments often cause serious long-term side effects including second cancer. New, safer therapies are urgently needed. Dr. Chen and colleagues will work with a gene called BRD1, which helps RMS cells move and invade other tissues. BRD1 controls another gene, MYOG, which is abnormally active in this cancer. When either gene is reduced, RMS cells become much less able to spread. Dr. Chen and colleagues will uncover how BRD1 and MYOG work together to drive metastasis and will identify the genes they regulate to serve as new drug targets. By revealing a new biological pathway that supports tumor spread, Dr. Chen and team will lay the foundation for more effective, less toxic treatments for children with high-risk RMS.